A phase II study of lenalidomide, zanubrutinib plus obinutuzumab in patients with FLIPI2 high-risk newly diagnosed follicular lymphoma: An interim analysis
Year: 2025
Type: conference-abstract
Source: Blood
Authors: Li Wang, Zhong Zheng, Ruichi Li, Pengpeng Xu, Shu Cheng, Wei Li Zhao
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4417006875
Cites:
Cited by:
Related to: